A Randomized, Double-blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of FP-025, an MMP-12 Inhibitor, in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs FP 025 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Foresee Pharmaceuticals
- 04 Dec 2017 Results published in the Foresee Pharmaceuticals media release.
- 04 Dec 2017 Status changed from active, no longer recruiting to completed, according to a Foresee Pharmaceuticals media release.
- 22 Sep 2017 Planned number of patients changed from 100 to 80.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History